
    
      This is a dose-response, double blind , placebo-controlled study. All patients are required
      to have 2 weeks washout period from prior medication. Subjects will discontinue current
      medications 2 weeks prior to randomization. Among those who meet the inclusion criteria, only
      subjects recording visual analogue scale(VAS) of higher than 40mm(VAS range from 0mm(no pain)
      to 100mm(unbearable pain)) are enrolled in this study.

      Subjects meeting screening criteria will be randomized to receive 8 weeks dosing of an active
      dose of SI000413 or placebo.
    
  